Skip to main content
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Complications

Effect of Antioxidant Treatment of Streptozotocin-Induced Diabetic Rats on Endoneurial Blood Flow, Motor Nerve Conduction Velocity, and Vascular Reactivity of Epineurial Arterioles of the Sciatic Nerve

  1. Lawrence J. Coppey,
  2. Jill S. Gellett,
  3. Eric P. Davidson,
  4. Joyce A. Dunlap,
  5. Donald D. Lund and
  6. Mark A. Yorek
  1. Diabetes Endocrinology Research Center, Veterans Affairs Medical Center, and the Department of Internal Medicine, University of Iowa, Iowa City, Iowa
    Diabetes 2001 Aug; 50(8): 1927-1937. https://doi.org/10.2337/diabetes.50.8.1927
    PreviousNext
    • Article
    • Figures & Tables
    • Info & Metrics
    • PDF
    Loading

    Article Figures & Tables

    Figures

    • Tables
    • FIG. 1.
      • Download figure
      • Open in new tab
      • Download powerpoint
      FIG. 1.

      Sciatic nerve Na+/K+ ATPase activity. For these studies, control rats, diabetic rats, and diabetic rats treated with either HES-DFO (DFO) or α-lipoic acid (αLA) were used to determine sciatic nerve Na+/K+ ATPase activity, as described in research design and methods. The duration of diabetes and treatments for these studies was 3–4 weeks. Data are presented as means ± SE for a minimum of eight separate samples. Sciatic nerve Na+/K+ ATPase activity in control rats treated with HES-DFO or α-lipoic acid was 296 ± 10 (n = 3) and 260 ± 44 (n = 3) μmol ADP · g wet wt−1 · h−1, respectively. *A significant difference compared with control rats.

    • FIG. 2.
      • Download figure
      • Open in new tab
      • Download powerpoint
      FIG. 2.

      Sciatic nerve sorbitol and myo-inositol content. Samples of the sciatic nerve from the animals described in Fig. 1 were used to determine the sorbitol and myo-inositol content, as described in research design and methods. Data are presented as means ± SE for a minimum of eight separate samples. *A significant difference compared with control rats; +a significant difference compared with untreated diabetic rats.

    • FIG. 3.
      • Download figure
      • Open in new tab
      • Download powerpoint
      FIG. 3.

      Serum triglyceride and free fatty acid (FFA) levels. Serum collected from animals described in Fig. 1 was used to determine the triglyceride and free fatty acid levels, as described in research design and methods. Data are presented as means ± SE for a minimum of eight separate samples. *A significant difference compared with control.

    • FIG. 4.
      • Download figure
      • Open in new tab
      • Download powerpoint
      FIG. 4.

      Liver and serum TBARSs. Liver and serum samples were collected from the animals described in Fig. 1 and used to determine TBARS level as described in research design and methods. Serum TBARSs in control rats treated with HES-DFO or α-lipoic acid were 4.8 ± 0.6 (n = 3) and 5.6 ± 1.2 (n = 3) μg/ml, respectively. Data are presented as means ± SE for a minimum of eight separate samples. *, A significant difference compared with control rats; +, a significant difference compared with untreated diabetic rats.

    • FIG. 5.
      • Download figure
      • Open in new tab
      • Download powerpoint
      FIG. 5.

      Lens GSH level. The lens was collected from the animals described in Fig. 1 and used to determine GSH level as described in research design and methods. Data are presented as means ± SE for a minimum of eight separate samples. Lens GSH level in control rats treated with HES-DFO or α-lipoic acid was 1.4 ± 0.2 (n = 3) and 1.6 ± 0.3 (n = 3) μg/mg wet wt, respectively. *, A significant difference compared with control; +, a significant difference compared with untreated diabetic rats.

    • FIG. 6.
      • Download figure
      • Open in new tab
      • Download powerpoint
      FIG. 6.

      Liver and sciatic nerve conjugated diene level. Samples of the liver and sciatic nerve were collected from the animals described in Fig. 1 and used to determine conjugated diene level as described in research design and methods. Data are presented as means ± SE for a minimum of eight separate samples. Sciatic nerve conjugated diene level in control rats treated with HES-DFO or α-lipoic acid was 2.7 ± 0.4 (n = 3) and 3.1 ± 1.5 (n = 3) μmol/mg wet wt, respectively. *, A significant difference compared with control rats.

    • FIG. 7.
      • Download figure
      • Open in new tab
      • Download powerpoint
      FIG. 7.

      Detection of superoxide level in arterioles from control rats, diabetic rats, and diabetic rats treated with either HES-DFO (DFO) or α-lipoic acid (αLA). The duration of diabetes and treatments for these studies was 3–4 weeks. Fluorescent photomicrographs of confocal microscopic sections of arterioles that provide circulation to the region of the sciatic nerve from the three individual groups of animals were examined on the same day. Arterioles were labeled with the oxidative dye hydroethidine as described in research design and methods. Recordings of fluorescence were taken at identical laser and photomultiplier settings for both control rats and untreated and treated diabetic rats. Shown is a representative sample of one set of animals. This experiment was repeated three separate times on separate sets of animals on three different days with similar results.

    • FIG. 8.
      • Download figure
      • Open in new tab
      • Download powerpoint
      FIG. 8.

      Determination of superoxide in the aorta using lucigenin-enhanced chemiluminescence. Samples of the aorta were collected from the animals described in Fig. 1 and used to determine superoxide level using lucigenin-enhanced chemiluminescence. Data are presented as mean RLUs ± SE for a minimum of eight separate samples. *A significant difference compared with control; +a significant difference compared with untreated diabetic rats.

    • FIG. 9.
      • Download figure
      • Open in new tab
      • Download powerpoint
      FIG. 9.

      Detection of peroxynitrite in arterioles from control rats, diabetic rats, and diabetic rats treated with either HES-DFO (DFO) or α-lipoic acid (αLA). Arterioles from control rats, untreated diabetic rats, and diabetic rats treated with either HES-DFO (DFO) or α-lipoic acid (αLA) were collected and treated for determination of 3-nitrotyrosine immunostaining as described in research design and methods. Shown is a representative sample of one set of animals. This experiment was repeated four separate times with similar results.

    • FIG. 10.
      • Download figure
      • Open in new tab
      • Download powerpoint
      FIG. 10.

      Determination of EBF. EBF reported as nutritive or conductance was determined for the same rats described in Table 1 and Fig. 1. EBF was determined as described in research design and methods. Data are presented as means ± SE for a minimum of eight separate samples. Nutritive EBF in control rats treated with HES-DFO or α-lipoic acid was 15.5 ± 5.6 (n = 3) and 15.3 ± 2.8 (n = 3) ml · min−1 · 100 g−1, respectively. *A significant difference compared with control rats; +a significant difference compared with untreated diabetic rats.

    • FIG. 11.
      • Download figure
      • Open in new tab
      • Download powerpoint
      FIG. 11.

      Determination of MNCV. MNCV was determined for the same rats described in Table 1 and Fig. 1. MNCV was determined as described in research design and methods. Data are presented as means ± SE for a minimum of eight separate samples. MNCV in control rats treated with HES-DFO or α-lipoic acid was 54.9 ± 3.0 (n = 3) and 51.3 ± 7.2 (n = 3) m/s, respectively. *A significant difference compared with control rats; +a significant difference compared with untreated diabetic rats.

    • FIG. 12.
      • Download figure
      • Open in new tab
      • Download powerpoint
      FIG. 12.

      Determination of the effect of treatment with HES-DFO or α-lipoic acid (αLA) on acetylcholine-mediated vascular relaxation in arterioles that provide circulation to the region of the sciatic nerve. Pressurized arterioles were constricted with U46619 (30–50%), and incremental doses of acetylcholine were added to the bathing solution while the steady-state vessel diameter was recorded. The number of experimental animals used in these studies was the same as that noted in Table 1. *Denotes that the response to acetylcholine was significantly attenuated in the diabetic rat; +denotes that the response to acetylcholine was significantly different compared with the untreated diabetic rats.

    Tables

    • Figures
    • TABLE 1

      Change in body weight and blood glucose levels

      AnimalChange in body weight (g)Blood glucose mg/dl
      Control (n = 9)119 ± 1197 ± 3
      Diabetic (n = 8)4 ± 8*424 ± 26*
      Diabetic + HES-DFO (n = 8)17 ± 11*450 ± 22*
      Diabetic + α-lipoic acid (n = 11)1 ± 11*373 ± 15*
      • Data are means ± SE.

      • *

        * P < 0.05 vs. control.

    PreviousNext
    Back to top

    In this Issue

    August 2001, 50(8)
    • Table of Contents
    • Index by Author
    Sign up to receive current issue alerts
    View Selected Citations (0)
    Print
    Download PDF
    Article Alerts
    Sign In to Email Alerts with your Email Address
    Email Article

    Thank you for your interest in spreading the word about Diabetes.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Effect of Antioxidant Treatment of Streptozotocin-Induced Diabetic Rats on Endoneurial Blood Flow, Motor Nerve Conduction Velocity, and Vascular Reactivity of Epineurial Arterioles of the Sciatic Nerve
    (Your Name) has forwarded a page to you from Diabetes
    (Your Name) thought you would like to see this page from the Diabetes web site.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Citation Tools
    Effect of Antioxidant Treatment of Streptozotocin-Induced Diabetic Rats on Endoneurial Blood Flow, Motor Nerve Conduction Velocity, and Vascular Reactivity of Epineurial Arterioles of the Sciatic Nerve
    Lawrence J. Coppey, Jill S. Gellett, Eric P. Davidson, Joyce A. Dunlap, Donald D. Lund, Mark A. Yorek
    Diabetes Aug 2001, 50 (8) 1927-1937; DOI: 10.2337/diabetes.50.8.1927

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    Add to Selected Citations
    Share

    Effect of Antioxidant Treatment of Streptozotocin-Induced Diabetic Rats on Endoneurial Blood Flow, Motor Nerve Conduction Velocity, and Vascular Reactivity of Epineurial Arterioles of the Sciatic Nerve
    Lawrence J. Coppey, Jill S. Gellett, Eric P. Davidson, Joyce A. Dunlap, Donald D. Lund, Mark A. Yorek
    Diabetes Aug 2001, 50 (8) 1927-1937; DOI: 10.2337/diabetes.50.8.1927
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Jump to section

    • Article
      • Abstract
      • RESEARCH DESIGN AND METHODS
      • RESULTS
      • DISCUSSION
      • Acknowledgments
      • Footnotes
      • REFERENCES
    • Figures & Tables
    • Info & Metrics
    • PDF

    Related Articles

    Cited By...

    More in this TOC Section

    • circRNA_010383 Acts as a Sponge for miR-135a, and Its Downregulated Expression Contributes to Renal Fibrosis in Diabetic Nephropathy
    • CaM Kinase II-δ Is Required for Diabetic Hyperglycemia and Retinopathy but Not Nephropathy
    • Connectivity Mapping Identifies BI-2536 as a Potential Drug to Treat Diabetic Kidney Disease
    Show more Complications

    Similar Articles

    Navigate

    • Current Issue
    • Online Ahead of Print
    • Scientific Sessions Abstracts
    • Collections
    • Archives
    • Submit
    • Subscribe
    • Email Alerts
    • RSS Feeds

    More Information

    • About the Journal
    • Instructions for Authors
    • Journal Policies
    • Reprints and Permissions
    • Advertising
    • Privacy Policy: ADA Journals
    • Copyright Notice/Public Access Policy
    • Contact Us

    Other ADA Resources

    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • Scientific Sessions Abstracts
    • Standards of Medical Care in Diabetes
    • BMJ Open - Diabetes Research & Care
    • Professional Books
    • Diabetes Forecast

     

    • DiabetesJournals.org
    • Diabetes Core Update
    • ADA's DiabetesPro
    • ADA Member Directory
    • Diabetes.org

    © 2021 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.